Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis BB-12
- Development stage
- Unknown
- Lead developer
- Medical University of Warsaw
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Bifidobacterium lactis BB-12** is a defined probiotic bacterial strain, also classified as *Bifidobacterium animalis* subsp. *lactis* BB-12. The Medical University of Warsaw evaluated it as an oral microbiome-modulating intervention in children with newly diagnosed type 1 diabetes mellitus, administered together with *Lactobacillus rhamnosus* GG once daily for 6 months. The rationale was that modulation of gut microbial ecology could influence intestinal barrier integrity and systemic immune responses relevant to autoimmune islet-cell destruction. In the completed randomized controlled trial, the BB-12 and LGG co-administration regimen did not significantly preserve residual pancreatic beta-cell function, measured using meal-stimulated C-peptide response. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03032354))
- Other names
- B. lactis Bb12BB-12BB12BB 12Bifidobacterium animalis subsp. lactis BB-12Bifidobacterium lactis Bb12
Beyond the preview
Go deeper on bifidobacterium lactis BB-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis BB-12.